Elsevier’s 2025 Intravenous Medications,

• Inaccessible, or known limited accessibility
  

Ways Of Reading

• This e-publication is accessible to the full extent that the file format and types of content allow, on a specific reading device, by default, without necessarily including any additions such as textual descriptions of images or enhanced navigation.
  

Navigation

• The contents of the PDF have been tagged to permit access by assistive technologies as per PDF-UA-1 standard.
  
• Page breaks included from the original print source
  

Additional Accessibility Information

• All (or substantially all) textual matter is arranged in a single logical reading order (including text that is visually presented as separate from the main text flow, e.g., in boxouts, captions, tables, footnotes, endnotes, citations, etc.). Non-textual content is also linked from within this logical reading order. (Purely decorative non-text content can be ignored).
  
• The language of the text has been specified (e.g., via the HTML or XML lang attribute) to optimise text-to-speech (and other alternative renderings), both at the whole document level and, where appropriate, for individual words, phrases or passages in a different language.
  

Conformance

• The publication was certified on 20250728
  
• Accessibility addendum
  
• For detailed accessibility information, see Elsevier’s website at https://www-elsevier-com.ucc.idm.oclc.org/about/accessibility
  
• For queries regarding accessibility information, contact [email protected]
  

Note

• This product relies on 3rd party tooling which may impact the accessibility features visible in inspection copies. All accessibility features mentioned would be present in the purchased version of the title.